Novartis AG 🇺🇸
NVS • Semiconductors • USA
💡 Institutional Quantitative Investment Thesis
High-quality compounder passing 7/9 fundamental checks. Strong balance sheet with Forward PER compression (17.1x vs 22.8x) and robust Free Cash Flow generation.
📊 Frequently Asked Questions & Related Moat Stocks
1. What is Novartis AG (NVS)'s Economic Moat Score in 2026?
In 2026, Novartis AG (NVS) holds a proprietary MoatPicks Economic Moat Score™ of 71.0/100 (Narrow-to-Wide Moat). This 12-point fundamental audit evaluates NVS's 75.0% gross margin, $11.9B free cash flow generation, +0.8% YoY revenue growth, and 2.1x Debt/EBITDA ratio. You can benchmark any stock's competitive durability interactively with our Economic Moat Score™ Checker.
2. Is NVS stock undervalued right now based on P/E and PEG ratio?
Yes — NVS currently screens as undervalued on a growth-adjusted basis with a Peter Lynch PEG ratio of 0.95x (below the 1.2x GARP threshold) and a Forward P/E of 17.1x. At a share price of $151.12, investors can stress-test NVS's fair value using the MoatPicks Economic Moat Score™ Checker and FIRE compounding calculators. Model how compounding NVS fits your long-term retirement target in our FIRE Financial Independence Calculator.
3. Which superinvestors and 13F hedge funds own NVS stock?
Novartis AG (NVS) is actively monitored across our 25 tracked 13F superinvestor portfolios and institutional quality screens. Institutional capital focuses on NVS's 75.0% gross margin, $11.9B free cash flow, and 2.1x Debt/EBITDA balance sheet.